Author

Ashwin Sannecy

Oregon Health & Science UniversityORCID 0000-0002-0675-9734Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Adel KardoshiD· 1 shared Alexander SmithiD· 1 shared Allison CreasoniD· 1 shared Aubry Matter· 1 shared Benson Chong· 1 shared Carl PelziD· 1 shared Charles D. LopeziD· 1 shared Christopher G. SuciuiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Adel KardoshORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathway

Motoyuki Tsuda, Dove J. Keith, Colin J. Daniel, Carl Pelz, Katie E. Blise, Tugba Y. Ozmen, Furkan Ozmen, Kevin Hawthone, Jennifer R. Eng, Xi Li, Xiaoyan Wang, Hayley Zimny, Shamilene Sivagnanam, Konjit Betre, Nell C. Kirchberger, , Rosalie C. Sears

The paper identifies resistance mechanisms to KRAS-MEK pathway targeting in PDAC by analyzing clinical trial data and multi-omics profiles, showing that KRAS/MYC co-gain correlates with resistance and that co-targeting these genes is synergistic.

bioRxiv · Dec 15, 2025 · PreprintCancer Biology